8-K - CervoMed Inc. (0001053691) (Filer)
Thu, Aug 1, 9:12 PM (88 days ago)
CervoMed Inc. reported key corporate updates on July 29, 2024, via Form 8-K. The company announced that plasma biomarker data from its AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies was featured at the Alzheimer's Association International Conference in Philadelphia. Additionally, on July 30, 2024, CervoMed disclosed that its management would participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024. These events highlight the company's ongoing clinical research and engagement with the investment community. The announcements may influence the company's stock value and financial position.